Travere Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on identifying, developing, and delivering life-changing therapies to people living with rare kidney and metabolic diseases. Its product, FILSPARI (sparsentan), is indicated to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression. FILSPARI is an oral, once-daily, non-immunosuppressive medication that directly targets glomerular injury in the kidney. Sparsentan is also in late-stage development for focal segmental glomerulosclerosis (FSGS). The Companyâs Pegtibatinase is a novel investigational human enzyme replacement candidate being evaluated for the treatment of classical homocystinuria (HCU), which is a rare metabolic disorder. Its commercial products, Thiola and Thiola EC, are for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTVTX
āļāļ·āđāļāļāļĢāļīāļĐāļąāļTravere Therapeutics Inc
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 23, 2003
āļāļĩāļāļĩāđāļDube (Eric M)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ385
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļJul 23
āļāļĩāđāļāļĒāļđāđ3611 Valley Centre Dr
āđāļĄāļ·āļāļSAN DIEGO
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ92130
āđāļāļĢāļĻāļąāļāļāđ18889697879
āđāļ§āđāļāđāļāļāđhttps://travere.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļTVTX
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļJul 23, 2003
āļāļĩāļāļĩāđāļDube (Eric M)
Dr. Eric M. Dube, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Jeffrey A. Meckler
Independent Director
Mr. Peter Heerma
Chief Commercial Officer
Mr. Gary A. Lyons
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Director
Dr. William E Rote, Ph.D.
Dr. William E Rote, Ph.D.
Chief Research Officer
Ms. Elizabeth E. Reed
Chief Legal Officer, General Counsel and Corporate Secretary
Chief Legal Officer, General Counsel and Corporate Secretary
Dr. Roy D. Baynes, M.D., Ph.D.
Dr. Roy D. Baynes, M.D., Ph.D.
Independent Director
Mr. John A. Orwin
Independent Director
Mr. Ron R. Squarer
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Dr. Eric M. Dube, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Jeffrey A. Meckler
Independent Director
Mr. Peter Heerma
Chief Commercial Officer
Mr. Gary A. Lyons
Independent Chairman of the Board
Independent Chairman of the Board
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Director
Dr. William E Rote, Ph.D.
Dr. William E Rote, Ph.D.
Chief Research Officer
Invesco Pharmaceuticals ETF
Innovator IBD 50 Fund ETF
Virtus LifeSci Biotech Products ETF
Invesco Dorsey Wright Healthcare Momentum ETF
Franklin Genomic Advancements ETF
ALPS Medical Breakthroughs ETF
First Trust Small Cap Growth AlphaDEX Fund
State Street SPDR S&P Biotech ETF
First Trust Multi-Manager Small Cap Opportunities ETF
Direxion Daily S&P Biotech Bull 3X Shares
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Invesco Pharmaceuticals ETF
āļŠāļąāļāļŠāđāļ§āļ5.39%
Innovator IBD 50 Fund ETF
āļŠāļąāļāļŠāđāļ§āļ4.05%
Virtus LifeSci Biotech Products ETF
āļŠāļąāļāļŠāđāļ§āļ3.77%
Invesco Dorsey Wright Healthcare Momentum ETF
āļŠāļąāļāļŠāđāļ§āļ2.96%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ1.51%
ALPS Medical Breakthroughs ETF
āļŠāļąāļāļŠāđāļ§āļ1.44%
First Trust Small Cap Growth AlphaDEX Fund
State Street SPDR S&P Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ0.77%
First Trust Multi-Manager Small Cap Opportunities ETF
āļŠāļąāļāļŠāđāļ§āļ0.73%
Direxion Daily S&P Biotech Bull 3X Shares
āļŠāļąāļāļŠāđāļ§āļ0.48%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ